



March 8, 2024
Kidswell Bio Corporation
Code: 4584 (Growth Market, TSE)
Shinya Kurebayashi, President & CEO

Notice of the Nomination of Candidates for Board Directors and Corporate Auditors

Kidswell Bio Corporation (“KWB”) announces that its Board of Directors, at a meeting held on March 8, 2024, decided on the following candidates for nomination to the Board of Director and Corporate Auditors and resolved to propose their election at the 24th Ordinary General Meeting of Shareholders to be held on June 26, 2024.

1. Director candidates

Name	Current title	Reappointed/Newly Appointed
Shinya Kurebayashi	Board Director	Reappointed
Yasuyuki Mitani	Corporate Officer, Chief Scientific Officer	Newly Appointed
Norikazu Eiki	Board Director	Reappointed
Sachiko Nishioka	-	Newly Appointed

Norikazu Eiki and Sachiko Nishioka are candidates for outside directors stipulated in the Companies Act.

2. Auditor candidates

Name	Current title	Reappointed/Newly Appointed
Osamu Sugawara	Corporate Auditor	Reappointed
Masato Mori	Corporate Auditor	Reappointed
Hiroshi Shinagawa	Corporate Auditor	Reappointed

Masato Mori and Hiroshi Shinagawa are candidates for outside auditors stipulated in the Companies Act.

3. Name and Career Summary of the New Candidates for Board of Directors

Name/Birthdate	Career Summary
Yasuyuki Mitani (Oct 18, 1973)	Mar 1996 BS, RPh, Faculty of Pharmaceutical Sciences, Kyoto University Mar 1998 MSc, Graduate School of Pharmaceutical Sciences, Kyoto University Apr 1998 Joined Astellas Pharma Inc. (f/k/a Fujisawa Pharmaceutical Co., Ltd.) Oct 2013 PhD, Graduate School of Pharmaceutical Sciences, The University of Tokyo Feb 2015 Post-doctoral fellow, Cincinnati Children's Hospital Medical Center, USA Sep 2017 Seconded to Buck Institute for Research on Aging, USA Apr 2019 Joined Kidswell Bio Corporation (f/k/a Gene Techno Science Co., Ltd.) Feb 2021 Head of Business Development, Regenerative Medicine Unit Leader Jun 2023 Corporate Officer, Chief Scientific Officer
Sachiko Nishioka (Jan 26, 1964)	Jul 1986 Joined Japan Airlines Co., Ltd. Apr 1988 Freelance announcer Jun 2000 MBA, University of Dallas Oct 2000 Joined Saison Information Systems as Assistant Manager, Corporate Planning Office Aug 2002 Jul 2006 Joined Publicis Japan as Strategic Planner Joined Gavin Anderson & Company Japan Inc. as Director Sep 2011 Part-time Lecturer at Hitotsubashi University Mar 2012 Established Plusna Communications Co., Ltd. as President

4. Reasons for the appointment

Yasuyuki Mitani has been leading the development of KWB's pipeline by initiating collaborative research with various academic institutions since KWB initiated the regenerative medicine business using stem cells from human exfoliated deciduous teeth (SHED). In addition, he has led the strategy formulation and R&D of SHED as Regenerative Medicine Unit Leader from 2021 and Corporate Officer and Chief Scientific Officer from 2023. His achievements include patent applications, the establishment of the master cell bank, and the promotion of clinical stage-up of cerebral palsy research.

He is expected to assume the position of President and CEO of S-Quatre Corporation, a wholly owned subsidiary of KWB to be established on April 1, 2024. The cell therapy business that S-Quatre plans to promote is key to the overall growth strategy of the KWB Group, as it will be a dramatic future growth driver for the KWB Group as a whole, and therefore it is considered optimal for him to execute the management of KWB Group as the Board Director responsible for this business.

Sachiko Nishioka has many years of experience in the communications field, including media, advertising and public relations and has been involved in corporate communications projects of a wide range of companies. She views communications as a management function and has established her own corporation to help clients to maximize their business opportunities by building good relationship with the stakeholders. Based on this experience, she has a wealth of relevant knowledge and is expected to provide useful feedback and advice to promote the continued growth of KWB's biosimilar business and the R&D and commercialization of SHED-based therapy both domestically and internationally. She has been nominated as a candidate for the position of Outside Director because KWB believes that she is also suitable for the role of overseeing KWB's business operations from an independent, fair and diverse perspectives.

5. Scheduled Date of Appointment

June 26, 2024, at the 24th Ordinary General Meeting of Shareholders

6. Resignation

Name	Current title
Masayuki Kawakami	Board Director

Masayuki Kawakami will join KWB as an employee after stepping down from Board Director and will continue to be responsible for clinical development as Corporate Officer and Chief Development Officer.